GIBSON DUNN

Gibson Dunn Advises Atossa Therapeutics on Establishing At-the-Market Facility for Sale of up to $50 Million of Common Stock

Firm News | February 20, 2026

Gibson Dunn represented Atossa Therapeutics, Inc. on establishing an at-the-market facility for the sale of up to $50 million of shares of its common stock.

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing innovative medicines in oncology and other areas of significant unmet need. The company's lead product candidate, (Z)-endoxifen, is currently in development across several clinical settings. Atossa is based in Seattle, Washington.

Gibson Dunn regularly advises life sciences companies on at-the-market equity offerings and other capital markets transactions.

The Gibson Dunn team included Ryan Murr, Melanie Neary, Nicholas Linke, and Anika Gidwani.

Related Capabilities

Capital Markets

Life Sciences

Related People

Ryan A. Murr

Melanie E. Neary

Nicholas G. Linke

Anika Gidwani

© 2026 Gibson, Dunn & Crutcher LLP. All rights reserved. For contact and other information, please visit us at www.gibsondunn.com. | **www.gibsondunn.com**